FDA’s Regulatory Rock And Hard Place: How To Handle Draft Guidances
Executive Summary
Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, which they argue puts companies in a difficult position.
You may also be interested in...
US FDA Considers Making More Guidance Final Without Public Comment
Increased use of the ‘immediate implementation’ provision in the agency’s Good Guidance Practices could help reduce stakeholder uncertainty.
US FDA Considers Making More Guidance Final Without Public Comment
Increased use of the ‘immediate implementation’ provision in the agency’s Good Guidance Practices could help reduce stakeholder uncertainty.
Biosimilar Approval Is New Focus In Senate Critique Of FDA Guidance Policy
Commissioner Hamburg describes a Catch-22, warning that pressure to finalize guidances faster without more resources could result in fewer discretionary guidances, disappointing stakeholders.